会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Substituted morpholine derivatives and their use as therapeutic agents
    • 取代的吗啉衍生物及其作为治疗剂的用途
    • US5612337A
    • 1997-03-18
    • US663201
    • 1996-06-13
    • Raymond BakerTimothy HarrisonAngus M. MacLeodAndrew P. OwensEileen M. SewardChristopher J. SwainMartin R. Teall
    • Raymond BakerTimothy HarrisonAngus M. MacLeodAndrew P. OwensEileen M. SewardChristopher J. SwainMartin R. Teall
    • C07D487/08A61K31/535A61K31/5377A61K31/541A61P1/08A61P25/00A61P25/04A61P25/06A61P25/28A61P29/00A61P43/00C07D413/06C07D413/14C07D417/14C07F9/6533C07F9/6558
    • C07D413/06C07D413/14C07F9/6533C07F9/65583
    • The present invention relates to compounds of formula (I), wherein R.sup.1 is hydrogen, halogen, C.sub.1-6 C alkyl, C.sub.1-6 alkoxy, CF.sub.3, NO.sub.2, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.1-4 alkyl substituted by C.sub.1-4 alkoxy, where R.sup.a and R.sup.b are hydrogen or C.sub.1-4 alkyl; R.sup.2 is hydrogen, halogen, C .sub.1-6 alkyl, C.sub.1-6 alkoxy substituted by C.sub.1-4 alkoxy or CF.sub.3 ; R.sup.3 is hydrogen, halogen or CF.sub.3 ; R.sup.4 is selected from the definitions of R.sup.1 ; R.sup.5 is selected from the definitions of R.sup.2 ; R.sup.6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by .dbd.O, .dbd.S or a C.sub.1-4 alkyl group, and optionally substituted by an aminoalkyl group; R.sup.9a and R.sup.9b are hydrogen or C.sub.1-4 alkyl, or R.sup.9a and R.sup.9b are joined to form a C.sub.5-7 ring; X is C.sub.1-4 alkylene optionally substituted by oxo; and Y is a C.sub.1-4 alkyl group optionally substituted by hydroxyl; with the proviso that if Y is C.sub.1-4 alkyl, R.sup.6 is substituted at least by an aminoalkyl group; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment of pain, inflammation, migraine and emesis.
    • PCT No.PCT / GB94 / 02819 Sec。 371日期:1996年6月13日 102(e)日期1996年6月13日PCT 1994年12月23日PCT公布。 公开号WO95 / 18124 日期:1995年7月6日(一)本发明涉及式(I)化合物,其中R 1为氢,卤素,C 1-6烷基,C 1-6烷氧基,CF 3,NO 2,CN,SR a,SOR a ,SO 2 R a,CO 2 R a,CONR a R b,C 2-6烯基,C 2-6炔基或被C 1-4烷氧基取代的C 1-4烷基,其中R a和R b是氢或C 1-4烷基; R2是氢,卤素,C 1-6烷基,被C 1-4烷氧基或CF 3取代的C 1-6烷氧基; R3是氢,卤素或CF3; R4选自R1的定义; R5选自R2的定义; R6是含有2或3个氮原子的5元或6元杂环,任选被= O,= S或C 1-4烷基取代,并且任选被氨基烷基取代; R9a和R9b是氢或C1-4烷基,或R9a和R9b连接形成C5-7环; X是任选被氧代取代的C 1-4亚烷基; Y是任选被羟基取代的C 1-4烷基; 条件是如果Y是C 1-4烷基,则R6至少被氨基烷基取代; 及其药学上可接受的盐和前药。 该化合物特别用于治疗疼痛,炎症,偏头痛和呕吐。
    • 4. 发明授权
    • Substituted amines as tachykinin receptor antagonists
    • 取代的胺作为速激肽受体拮抗剂
    • US5554633A
    • 1996-09-10
    • US374746
    • 1995-01-27
    • Martin R. Teall
    • Martin R. Teall
    • C07D213/40C07D307/52A61K31/34A61K31/44
    • C07D213/40C07D307/52
    • Compounds of formula (I), and salts and prodrugs thereof, wherein Q is optionally substituted phenyl or benzhydryl; X and Y are each H or together form a group=O; Z is O, S or NR.sup.9, where R.sup.9 is H or C.sub.1-6 alkyl; R.sup.1 represents H or C.sub.1-6 alkyl; R.sup.2 represents C.sub.1-6 alkyl substituted by CONR.sup.7 (CH.sub.2).sub.p R.sup.8 (where R.sup.7 is H or C.sub.1-6 alkyl, R.sup.8 is optionally substituted heteroaryl and p is 0, 1, 2, 3, 4, 5 or 6); R.sup.3 represents H, C.sub.1-6 alkyl or C.sub.2-6 alkynyl; R.sup.4 represents H, C.sub.1-6 alkyl or optionally substitute phenyl; R.sup.5 represents optionally substituted phenyl; R.sup.6 is H or C.sub.1-6 alkyl; and q is 0, 1, 2 or 3; are tachykinin antagonists useful in therapy.
    • 式(I)化合物及其盐和前药,其中Q为任选取代的苯基或二苯甲基; X和Y各自为H或一起形成基团= O; Z是O,S或NR 9,其中R 9是H或C 1-6烷基; R1表示H或C1-6烷基; R 2表示被CONR 7(CH 2)p R 8取代的C 1-6烷基(其中R 7为H或C 1-6烷基,R 8为任选取代的杂芳基且p为0,1,2,3,4,5或6)。 R3表示H,C1-6烷基或C2-6炔基; R 4表示H,C 1-6烷基或任选地取代苯基; R5代表任选取代的苯基; R6是H或C1-6烷基; q为0,1,2或3; 是用于治疗的速激肽拮抗剂。